tirzepatide clinical trials Tirzepatide's Surmount-4 Trial Reveals Groundbreaking Results SURMOUNT-3 study design This is

However, they also reported an increased risk of certain medical complications, including myocardial infarction (MI) and acute kidney injuryfindings that contradict earlier literature

Molecular Class: Synthetic insulin-like growth factor analog research peptide Peptide Composition: Modified single-chain peptide (IGF-1 LR3) Purity: Research-grade, high-purity peptide material Material State: Lyophilized peptide powder Quantity: 1mg per vial Intended Use: Laboratory research only Research Applications Within scientific and preclinical literature, IGF-1 LR3 1mg is referenced as a synthetic research peptide evaluated exclusively in controlled, non-clinical laboratory environments

Cell (2017) 171(2):27385

For tirzepatide, the equivalent range sits around 0.5 mg to 1.25 mg weekly